Novo Nordisk

425.35

DKK

+2.67 %

Less than 1K followers

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+2.67%

-10.27%

-30.36%

-31.86%

-44.8%

-52.02%

+10.37%

+89.89%

+34,064.66%

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Market cap

1.9T DKK

Turnover

768.76M DKK

Revenue

290.4B

EBIT %

44.19 %

P/E

18.76

Dividend yield-%

2.68 %

Financial calendar

7/5

2025

Interim report Q1'25

6/8

2025

Interim report Q2'25

5/11

2025

Interim report Q3'25

All

Press releases

ShowingAll content types

Regulatory press release4/3/2025, 6:00 AM

Novo Nordisk announces changes in Executive Management

Press release3/29/2025, 6:33 PM

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Press release3/29/2025, 2:33 PM

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release3/27/2025, 3:16 PM

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Press release3/24/2025, 10:01 AM

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Regulatory press release3/10/2025, 10:23 AM

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Regulatory press release2/27/2025, 2:03 PM

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Regulatory press release2/7/2025, 12:54 PM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Press release2/7/2025, 7:45 AM

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Regulatory press release2/6/2025, 9:12 AM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Press release2/5/2025, 12:36 PM

Novo Nordisk files annual report with the SEC

Regulatory press release2/5/2025, 6:30 AM

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Regulatory press release2/4/2025, 12:57 PM

Novo Nordisk A/S - share repurchase programme

Regulatory press release1/27/2025, 1:04 PM

Novo Nordisk A/S - share repurchase programme

Regulatory press release1/24/2025, 10:19 AM

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Regulatory press release1/20/2025, 2:32 PM

Novo Nordisk A/S - share repurchase programme

Regulatory press release1/17/2025, 12:11 PM

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

Press release1/8/2025, 11:30 AM

Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

Regulatory press release12/20/2024, 12:47 PM

Novo Nordisk A/S - share repurchase programme

Regulatory press release12/20/2024, 10:41 AM

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.